Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Standard Biotools (LAB) Net Cash Flow (2016 - 2025)

Standard Biotools (LAB) has disclosed Net Cash Flow for 16 consecutive years, with -$8.6 million as the latest value for Q4 2025.

  • Quarterly Net Cash Flow rose 79.91% to -$8.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$46.4 million through Dec 2025, down 139.59% year-over-year, with the annual reading at -$46.4 million for FY2025, 139.59% down from the prior year.
  • Net Cash Flow for Q4 2025 was -$8.6 million at Standard Biotools, up from -$29.0 million in the prior quarter.
  • The five-year high for Net Cash Flow was $235.9 million in Q1 2024, with the low at -$62.5 million in Q3 2023.
  • Average Net Cash Flow over 5 years is -$90789.5, with a median of -$15.7 million recorded in 2025.
  • The sharpest move saw Net Cash Flow tumbled 581.95% in 2021, then surged 1885.84% in 2023.
  • Over 5 years, Net Cash Flow stood at -$39.2 million in 2021, then surged by 153.05% to $20.8 million in 2022, then crashed by 235.52% to -$28.2 million in 2023, then tumbled by 52.06% to -$42.9 million in 2024, then soared by 79.91% to -$8.6 million in 2025.
  • According to Business Quant data, Net Cash Flow over the past three periods came in at -$8.6 million, -$29.0 million, and $6.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.